Evidence map›Paper›PMID 33997269›Full record

ArticleAdvanced therapeutics2021

Targeting glioblastoma using a novel peptide specific to a deglycosylated isoform of brevican.

Niklas von Spreckelsen, Colin M Fadzen, Nina Hartrampf, Yarah Ghotmi, Justin M Wolfe, Shipra Dubey, Bo Yeun Yang, Marie F Kijewski, Shuyan Wang, Charlotte Farquhar and 15 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Understanding Glioblastoma Dynamics Using 3D Organoids and Engineered Extracellular Matrix.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Landscape of surfaceome and endocytome in human glioma is divergent and depends on cellular spatial organization.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 9 institutions in 5 countries.

Niklas von SpreckelsenHarvey Cushing Neuro-Oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, United States.
Colin M FadzenDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.
Nina HartrampfDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.
Yarah GhotmiHarvey Cushing Neuro-Oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, United States.
Justin M WolfeDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.
Shipra DubeyDepartment of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA02115, United States.
Bo Yeun YangDepartment of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA02115, United States.
Marie F KijewskiDepartment of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA02115, United States.
Shuyan WangDepartment of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA02115, United States.
Charlotte FarquharDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.
Sonja BergmannHarvey Cushing Neuro-Oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, United States.
Mykola ZdiorukHarvey Cushing Neuro-Oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, United States.
J Roscoe WasserburgHarvey Cushing Neuro-Oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, United States.
Benjamin ScottHarvey Cushing Neuro-Oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, United States.
Emily MurrellDepartment of Chemistry, University of Western Ontario, London, ON N6C 4K3 Canada.
Fernanda C BononiDepartment of Chemistry, University of Western Ontario, London, ON N6C 4K3 Canada.
Leonard G LuytDepartment of Chemistry, University of Western Ontario, London, ON N6C 4K3 Canada.
Marcelo DiCarliDepartment of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA02115, United States.
Martine L M LamfersDepartment of Neurosurgery, Brain Tumor Center, Erasmus Medical Center, Rotterdam, the Netherlands.
Keith L LigonDepartment of Pathology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, United States.
E Antonio ChioccaHarvey Cushing Neuro-Oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, United States.
Mariano S ViapianoDepartment of Neuroscience and Physiology, State University of New York Upstate Medical University, Syracuse, New York 13210.
Bradley L PenteluteDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.
Sean E LawlerHarvey Cushing Neuro-Oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, United States.
Choi-Fong ChoHarvey Cushing Neuro-Oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, United States.
Harvard University · USBrigham and Women's Hospital · USMassachusetts Institute of Technology · USWestern University · CADana-Farber Cancer Institute · USErasmus MC · NLSUNY Upstate Medical University · USUniversity Hospital Cologne · DEZHAW Zurich University of Applied Sciences · CH

Funding

Fluorinated macrocyclic peptides as BBB penetrating agent for improved GBM treatmentR01CA237063 · NCI · BROWN UNIVERSITY · PI LAWLER, SEAN EDWARD, PENTELUTE, BRADLEY LETHER · 2019 to 2023
$3.0M
Indirubins: novel anti-invasive and anti-angiogenic drugs for malignant gliomasR01CA166172 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI CHIOCCA, E. ANTONIO · 2013 to 2017
$1.8M
NCI NIH HHS R01 CA166172NCI NIH HHS R01 CA237063
6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) is the most common and deadliest form of brain tumor and remains amongst the most difficult cancers to treat. Brevican (Bcan), a central nervous system (CNS)-specific extracellular matrix protein, is upregulated in high-grade glioma cells, including GBM. A Bcan isoform lacking most glycosylation, dg-Bcan, is found only in GBM tissues. Here, dg-Bcan is explored as a molecular target for GBM. In this study, we screened a d-peptide library to identify a small 8-amino acid dg-

Indexed as

glioblastomamolecular targetingpeptidePET imaging

Identifiers

PMID33997269
PMCPMC8114962
OpenAlexW3124222970

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.